Nixon Ronald T reported grant involving 4,154 shares of Sanara MedTech Inc. at $0.00 for $0 on Jun 4, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
4,154Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
68,196Direct
Trade date
Jun 4, 2026Grant
Filed
Jun 5, 2026, 8:31 PM ET2-day reporting delay
Accession
0001493152-26-027590Code A · Transaction 99126
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

SMTI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SMTI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Jun 13, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date. F2: Represents shares of the Issuer's common stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the common stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any common stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein. F3: Represents shares of the Issuer's common stock owned of record by FA Sanara, LLC ("FA Sanara"). FA Sanara is managed by Family Alignment, LLC ("Family"), which is managed by Catalyst Group, Inc. ("Catalyst"). Mr. Nixon is a controlling shareholder and President of Catalyst. Mr. Nixon, Catalyst, Family and FA Sanara may be deemed to share voting and dispositive control over the common stock. Mr. Nixon, Catalyst and Family disclaim beneficial ownership of any common stock held or beneficially owned by FA Sanara, except to the extent of each of their pecuniary interests therein.